Literature DB >> 12702959

The natural history of dysplasia and cancer in esophagitis and Barrett esophagus.

Stuart Jon Spechler1.   

Abstract

The natural history of metaplasia and dysplasia in Barrett esophagus is not well defined. Publication bias, the selective reporting of studies that have positive or extreme results, has exaggerated the risk of esophageal adenocarcinoma in this condition. Recent data suggest that patients with Barrett esophagus develop these tumors at the rate of 0.5% per year, a cancer incidence considerably lower than was appreciated just a few years ago. Indirect evidence suggests that aggressive treatment of gastroesophageal reflux might decrease the risk of carcinogenesis, but no therapy yet has been proved to decrease the incidence of cancer in Barrett esophagus. Dysplasia in the metaplastic epithelium clearly is a worrisome finding, but the progression from dysplasia to cancer may take years and may not be inevitable.

Entities:  

Mesh:

Year:  2003        PMID: 12702959     DOI: 10.1097/00004836-200305001-00002

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  9 in total

1.  Barrett's esophagus and the increasing role of endoluminal therapy.

Authors:  Michael S Smith; Charles J Lightdale
Journal:  Therap Adv Gastroenterol       Date:  2008-09       Impact factor: 4.409

2.  Barrett's esophagus: prevalence and risk factors in patients with chronic GERD in Upper Egypt.

Authors:  Yasser M Fouad; Madiha M Makhlouf; Heba M Tawfik; Hussein el-Amin; Wael Abdel Ghany; Hisham R el-Khayat
Journal:  World J Gastroenterol       Date:  2009-07-28       Impact factor: 5.742

3.  A Comparison Study of Esophageal Findings on (18)F-FDG PET/CT and Esophagogastroduodenoscopy.

Authors:  KwanHyeong Jo; Soyoung Kim; Jongtae Cha; Sang Hyun Hwang; Narae Lee; Mijin Yun; Won Jun Kang
Journal:  Nucl Med Mol Imaging       Date:  2015-10-16

Review 4.  Two-year follow-up period showing the natural history of a superficial esophageal adenocarcinoma arising in a long segment of Barrett's esophagus.

Authors:  Junya Oguma; Soji Ozawa; Akihito Kazuno; Miho Nitta; Yamato Ninomiya; Sakura Tomita
Journal:  Clin J Gastroenterol       Date:  2016-09-02

5.  Esophagectomy for high grade dysplasia is safe, curative, and results in good alimentary outcome.

Authors:  Valerie A Williams; Thomas J Watson; Fernando A Herbella; Oliver Gellersen; Daniel Raymond; Carolyn Jones; Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2007-10-02       Impact factor: 3.452

Review 6.  Management strategies of Barrett's esophagus.

Authors:  Giovanni D De Palma
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742

7.  Advances in Endoscopic Visualization of Barrett's Esophagus: The Role of Confocal Laser Endomicroscopy.

Authors:  Helga Bertani; Flavia Pigò; Emanuele Dabizzi; Marzio Frazzoni; Vincenzo Giorgio Mirante; Mauro Manno; Raffaele Manta; Rita Conigliaro
Journal:  Gastroenterol Res Pract       Date:  2012-03-14       Impact factor: 2.260

8.  Proton Pump Inhibitors Diminish Barrett's Esophagus Length: Our Experience.

Authors:  Zaim Gashi; Elton Bahtiri; Arjeta Gashi; Fadil Sherifi
Journal:  Open Access Maced J Med Sci       Date:  2018-06-08

9.  Ki-67 Antigen Overexpression Is Associated with the Metaplasia-Adenocarcinoma Sequence in Barrett's Esophagus.

Authors:  Bernardo Silveira Volkweis; Richard Ricachenevsky Gurski; Luise Meurer; Guilherme Gonçalves Pretto; Guilherme da Silva Mazzini; Maria Isabel Edelweiss
Journal:  Gastroenterol Res Pract       Date:  2012-07-11       Impact factor: 2.260

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.